RxDoctor Payments Data

Michael Alexander, MD

Internal Medicine · Lafayette, LANPI 1649352261

Payments from drug & device makers

$8,449in general payments, 2019–2025

Across 594 payments — averaging $14.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$1K
  • AstraZeneca$726
  • Pfizer$721
  • AbbVie$711
  • Novo Nordisk$675
  • Amgen$434
  • plus $4K from 39 others

What the payments were for

  • Food & beverage$8,421100%
  • Education$280%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,449 in reported general payments places this provider in the 90th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$260,935
Medicare patients
640
Services billed
2,858

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin213$182,734
MounjaroTirzepatide131$139,294
EliquisApixaban154$132,244
OzempicSemaglutide105$109,076
FarxigaDapagliflozin Propanediol97$79,094
XareltoRivaroxaban68$62,942
TrulicityDulaglutide32$35,001
Repatha SureclickEvolocumab30$22,110
JanuviaSitagliptin Phosphate26$20,206
Tresiba Flextouch U-200Insulin Degludec26$15,389
KerendiaFinerenone11$13,323
EntrestoSacubitril/Valsartan20$12,886
RybelsusSemaglutide12$11,439
SynthroidLevothyroxine Sodium127$9,549
TrintellixVortioxetine Hydrobromide16$7,452

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$184$182,734213 claims
Lilly USA, LLCMounjaro, Trulicity$1,210$174,295163 claims
PfizerEliquis$721$132,244154 claims
Novo NordiskOzempic, Rybelsus$675$120,515117 claims
AstraZenecaFarxiga$726$79,09497 claims
Johnson & JohnsonXarelto, Invokana$334$70,26181 claims
MerckJanuvia, Janumet$87$22,72137 claims
BayerKerendia$175$13,32311 claims
NovartisEntresto$265$12,88620 claims
AbbVieSynthroid$711$9,549127 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$371$7,45216 claims
GSKArnuity Ellipta$230$7,00116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Lafayette

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →